Quarterly ResultNov 6, 2026, 09:06 AM
Immunocore Q3 Net Loss $14.2M; Revenue $102.2M
AI Summary
Immunocore Holdings plc reported its third-quarter financial results, showing a net loss of $14.22 million, or $0.28 per share, compared to a net loss of $0.18 million in the same period last year. Revenue from the sale of therapies was $102.22 million, a slight decrease from $103.69 million in the prior year's quarter. The company's balance sheet shows an increase in total assets to $1.13 billion and a healthy cash position of $512.25 million. The filing also details ongoing clinical programs and forward-looking statements regarding therapeutic potential and market expansion.
Key Highlights
- Revenue from sale of therapies was $102.22M for Q3 2026, a slight decrease from $103.69M in Q3 2025.
- Net loss for Q3 2026 was $14.22M, compared to a net loss of $0.18M in Q3 2025.
- Basic and diluted net loss per share was $0.28 for Q3 2026, versus $0.00 for Q3 2025.
- Total assets increased to $1.13B as of September 30, 2026, from $1.07B as of December 31, 2025.
- Cash and cash equivalents stood at $512.25M as of September 30, 2026, up from $467.71M as of December 31, 2025.
- Interest-bearing loans and borrowings remained stable at $394.75M as of September 30, 2026.
Price Impact
More from IMCR